Evidence map›Paper›PMID 36918112›Full record

ArticleThe American journal of the medical sciences2023

Serum antibodies to peptidylarginine deiminase-4 in rheumatoid arthritis associated-interstitial lung disease are associated with decreased lung fibrosis and improved survival.

Timothy M Wilson, Joshua J Solomon, Stephen M Humphries, Jeffrey J Swigris, Faduma Ahmed, Hong Wang, Erika Darrah, M Kristen Demoruelle

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The American journal of the medical sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Timothy M WilsonDivision of Rheumatology, Department of Medicine, Thomas Jefferson University, Philadelphia, PA, USA. Electronic address: timothy.wilson@jefferson.edu.
Joshua J SolomonDivision of Pulmonary Critical Care and Sleep Medicine, Department of Medicine, National Jewish Health, Denver, CO, USA.
Stephen M HumphriesDivision of Pulmonary Critical Care and Sleep Medicine, Department of Medicine, National Jewish Health, Denver, CO, USA.
Jeffrey J SwigrisDivision of Pulmonary Critical Care and Sleep Medicine, Department of Medicine, National Jewish Health, Denver, CO, USA.
Faduma AhmedDivision of Pulmonary Critical Care and Sleep Medicine, Department of Medicine, National Jewish Health, Denver, CO, USA.
Hong WangDivision of Rheumatology, Department of Medicine, The Johns Hopkins University, Baltimore, MD, USA.
Erika DarrahDivision of Rheumatology, Department of Medicine, The Johns Hopkins University, Baltimore, MD, USA.
M Kristen DemoruelleDivision of Rheumatology, Department of Medicine, University of Colorado Denver, Aurora, CO, USA.
National Jewish Health · USJohns Hopkins University · USThomas Jefferson University · USUniversity of Colorado Denver · US

Funding

Research Training in Rheumatology INCLUDE Down Syndrome SupplementT32AR007534 · NIAMS · UNIVERSITY OF COLORADO DENVER · PI Kristine A. Kuhn · 1986 to 2026
$6.1M
The Lung as an Originating Site of Autoimmunity in Rheumatoid ArthritisK23AR066712 · NIAMS · UNIVERSITY OF COLORADO DENVER · PI DEMORUELLE, M. KRISTEN · 2014 to 2018
$776k
NIAMS NIH HHS K23 AR066712NIAMS NIH HHS T32 AR007534
6 · The paper itself

Abstract

objectiveInterstitial lung disease (ILD) is a leading cause of mortality in rheumatoid arthritis (RA), particularly in those with the usual interstitial pneumonia subtype (RA-UIP). Serum antibodies to peptidylarginine deiminase type 4 (anti-PAD4), particularly a subset that cross-react with PAD3 (PAD3/4XR), have been associated with imaging evidence of ILD. We aimed to determine the specificity of anti-PAD4 antibodies in RA-ILD and to examine associations with markers of ILD severity.

methods48 RA-ILD and 31 idiopathic pulmonary fibrosis (IPF) patients were identified from the National Jewish Health Biobank. RA-ILD subtype was defined by imaging pattern on high-resolution chest computed tomography (CT), and serum was tested for anti-PAD4 and anti-PAD3/4XR antibodies. Antibody prevalence, measures of ILD severity (% predicted forced vital capacity, FVC; % predicted diffusion capacity carbon monoxide, DLCO; quantitative CT fibrosis) and mortality were compared between groups.

resultsAnti-PAD4 antibodies were present in 9/48 (19%) subjects with RA-ILD and no subjects with IPF. Within RA-ILD, anti-PAD4 antibodies were found almost exclusively in RA-UIP (89%). Within RA-UIP subjects, % predicted FVC was higher in anti-PAD4+ subjects, and this finding was most strongly associated with anti-PAD3/4XR antibodies. In addition, quantitative CT fibrosis score was lower in anti-PAD4+ RA-UIP subjects, including those with mono-reactive anti-PAD4 antibodies and anti-PAD3/4XR antibodies. Anti-PAD4+ RA-UIP subjects also exhibited decreased mortality.

conclusionsWe demonstrate the presence of serum anti-PAD4 antibodies in a subset of patients with RA-UIP that were notably associated with better lung function, less fibrosis and decreased mortality.

Indexed as

Arthritis, RheumatoidIdiopathic Pulmonary FibrosisLung Diseases, InterstitialAutoantibodiesHumansProtein-Arginine Deiminase Type 4AutoantibodiesProtein-Arginine Deiminase Type 4ILDIPFPAD4Rheumatoid arthritis

Identifiers

PMID36918112
PMCPMC10247162
OpenAlexW4323975463

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.